2024 |
Martin JH, Galettis P, Flynn A, Schneider J, 'Phenotype versus genotype to optimize cancer dosing in the clinical setting-focus on 5-fluorouracil and tyrosine kinase inhibitors.', Pharmacol Res Perspect, 12 e1182 (2024)
|
|
|
2024 |
Radovanovic M, Galettis P, Flynn A, Martin JH, Schneider JJ, 'Paclitaxel and Therapeutic Drug Monitoring with Microsampling in Clinical Practice', Pharmaceuticals, 17 (2024) [C1]
|
|
Nova |
2023 |
Chin PKL, Charles K, Murnion B, McGuire TM, Hilmer SN, Martin J, et al., 'Evaluation of the Prescribing Skills Assessment implementation, performance and medical student experience in Australia and New Zealand.', Br J Clin Pharmacol, 89 3105-3115 (2023) [C1]
|
|
Nova |
2023 |
Graham M, Renaud E, Lucas CJ, Schneider J, Martin JH, 'Medicinal Cannabis Guidance and Resources for Health Professionals to Inform Clinical Decision Making.', Clin Ther, 45 527-534 (2023) [C1]
|
|
Nova |
2022 |
Graham M, Martin JH, Lucas CJ, Murnion B, Schneider J, 'Cannabidiol drug interaction considerations for prescribers and pharmacists', EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 15 1383-1397 (2022) [C1]
|
|
Nova |
2022 |
Schneider J, Felkai C, Munro I, 'A Comparison of Real and Virtual Laboratories for Pharmacy Teaching.', Pharmacy (Basel, Switzerland), 10 133 (2022) [C1]
|
|
Nova |
2022 |
Graham M, Bird S, Howard Z, Dobson M, Palazzi K, Lucas CJ, et al., 'NSW Cannabis Medicines Advisory Service preliminary survey results: enquirer perceptions and patient outcomes.', Intern Med J, 52 228-237 (2022) [C1]
|
|
Nova |
2022 |
Radovanovic M, Schneider JJ, Shafiei M, Martin JH, Galettis P, 'Measurement of 5- fluorouracil, capecitabine and its metabolite concentrations in blood using volumetric absorptive microsampling technology and LC-MS/MS', Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 1188 (2022) [C1]
5-fluorouracil (5-FU) and its oral formulation, capecitabine, are widely used in treating a range of malignancies, either alone or in combination with other antineoplastic drugs. ... [more]
5-fluorouracil (5-FU) and its oral formulation, capecitabine, are widely used in treating a range of malignancies, either alone or in combination with other antineoplastic drugs. Body surface area-based dosing is used for these agents, despite this approach leading to substantial variability in drug exposure and often resulting in either toxicity or treatment failure. Tailoring therapeutic regimens for individual patients using therapeutic drug monitoring (TDM) has been shown to significantly reduce toxicity and improve cancer outcomes. However, for optimum TDM, sample timing is crucial, along with the need for a venepuncture blood sample to obtain the plasma currently used for 5-FU measurement. In addition to complex blood sample handling requirements, large sample volume and frequent sampling required for pharmacokinetic analysis is another barrier to successfully implementing TDM in a healthcare setting. Microsampling is an alternative collection method to venepuncture, which, combined with the now readily available liquid chromatography mass spectrometry (LC-MS/MS) technology, overcomes the plasma-associated issues. It also has the significant advantage of enabling at home and remote sampling, thus facilitating 5-FU TDM in clinical practice. A LC-MS/MS method for simultaneous measurement of capecitabine, 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine and 5-FU using Mitra® microsampling devices for sample collection was developed. A Shimadzu 8060 LC-MS/MS equipped with electrospray ionisation source interface, operated in positive and negative ion modes, with reversed-phase chromatographic separation was employed for sample analysis. Samples were extracted from Mitra® devices using acetonitrile containing stable isotope-labelled internal standards, sonicated, evaporated under vacuum and resuspended in 0.1 % formic acid before injection into the LC-MS/MS. Chromatographic separation was on a Luna Omega Polar C18 (100 × 2.1 mm, 1.6 µm) column with gradient elution of 0.1 % formic acid in water and acetonitrile. Total run time was 5 min, with the injection volume of 1 µL. The intra and inter-day imprecision ranged from 3.0 to 8.1 and 6.3¿13.3 % respectively. Accuracy ranged from 95 -114 % for all analytes. Lower limit of quantification with imprecision of < 19 % and accuracy between 89 and 114 % was 0.05 mg/L for 5-FU and 10 µg/L for other analytes. Assays were linear from 0.05 to 50 mg/L for 5-FU and 10¿10,000 µg/L for all other analytes. Analytes were stable on Mitra® devices for up to 9 months at room temperature, 2 years at -30 ¿ and 3 days at 50 ¿. The method was successfully applied for the analysis of samples from patients undergoing cancer treatment with 5-FU and capecitabine. Microsampling using volumetric absorptive microsampling proved to be as reliable as conventional blood collection for 5-FU and capecitabine. This sampling technique may lead to less invasive and better-timed sample collection for TDM, supporting dose optimization strategy.
|
|
Nova |
2021 |
Miller P, Newby D, Walkom E, Schneider J, Li SC, Evans TJ, 'The performance and accuracy of depression screening tools capable of self-administration in primary care: A systematic review and meta-analysis', European Journal of Psychiatry, 35 1-18 (2021) [C1]
Background and Objectives: The US Preventative Services Taskforce recommends screening adults for depression in primary care where adequate systems are established to ensure accur... [more]
Background and Objectives: The US Preventative Services Taskforce recommends screening adults for depression in primary care where adequate systems are established to ensure accurate diagnosis, effective treatment and follow-up. However, there is currently no consensus on which screening tool is most suitable for use in primary healthcare. We aim to systematically review the literature for operating characteristics of depression screening tools capable of self-administration in primary healthcare and meta-analyse the psychometric characteristics of these tools to determine their performance and accuracy. Methods: An electronic literature search of EMBASE, Medline and CINAHL Complete was conducted from January 1982 to September 15, 2019 using the keywords: depression, screening, primary healthcare and adult. General and psychometric characteristics were extracted for screening tools studied in primary healthcare only when assessed against a ¿reference-standard¿. Results: Eighty-one studies from 22 countries were included in the review. Forty unique depression screening tools suitable for self-administration were identified in studies yielding 138 psychometric data sets. Based on ease of administration, 18 screening tools were suitable for use in primary healthcare. Of the tools meta-analysed, only the PHQ-9 and WHO-5 displayed superior accuracy and were easily administered. Conclusion: Although numerous depression screening tools are suitable for use in primary care based on ease of administration, the PHQ-9 was the most widely assessed tool and displayed superior DOR, a-ROC, specificity and LR +. Our review supports the use of the PHQ-9 as a brief, easily administered depression screening tool with superior discriminatory performance and robust psychometric characteristics in primary care settings.
|
|
Nova |
2021 |
Erku D, Schneider J, Scuffham P, 'A framework for economic evaluation of therapeutic drug monitoring-guided dosing in oncology', PHARMACOLOGY RESEARCH & PERSPECTIVES, 9 (2021) [C1]
|
|
Nova |
2021 |
Schneider JJ, Galettis P, Martin JH, 'Overcoming barriers to implementing precision dosing with 5-fluorouracil and capecitabine', BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 87 317-325 (2021) [C1]
|
|
Nova |
2020 |
Miller P, Newby D, Walkom E, Schneider J, Li SC, 'Depression screening in adults by pharmacists in the community: a systematic review', International Journal of Pharmacy Practice, 28 428-440 (2020) [C1]
|
|
Nova |
2020 |
Liu Z, Galettis P, Broyd SJ, van Hell H, Greenwood LM, de Krey P, et al., 'Model-based analysis on systemic availability of co-administered cannabinoids after controlled vaporised administration', Internal Medicine Journal, 50 846-853 (2020) [C1]
Background: The most important two medicinal cannabinoids are ¿9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Vaporised administration is superior due to its higher systemic ... [more]
Background: The most important two medicinal cannabinoids are ¿9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Vaporised administration is superior due to its higher systemic availability, lower individual variability and faster drug delivery. Although it is common THC is co-administered with CBD, the influence of CBD on the pharmacokinetics, especially the systemic availability of THC after vaporised administration, is unknown. Aims: To investigate the influence of different doses of co-administered CBD on the systemic availability of THC, and to compare the availability of THC and CBD in a sample of frequent and infrequent cannabis users. Methods: The study used a randomised, double-blind, crossover placebo-controlled design. THC and/or CBD in ethanol was vaporised and inhaled. Plasma concentrations of THC and CBD were analysed. The THC data created in this study were pooled together with published THC pharmacokinetic data in order to cover all the phases of THC disposition. Population pharmacokinetic model of THC was developed based on the pooled data. The model of CBD was developed based on the data created in this study. Results: Population pharmacokinetic models of THC and CBD were developed. With concomitant inhalation of high-dose CBD, the systemic availability of THC decreased significantly. Frequent cannabis users appeared to have higher systemic availability of THC and CBD when high-dose CBD was administered. Conclusions: The results observed in this study are useful for guiding future pharmacokinetic studies of medicinal cannabinoids, and for development of dosing guidelines for medical use of cannabis in the ¿real-world¿ setting.
|
|
Nova |
2020 |
Salem S, Cooper J, Schneider J, Croft H, Munro I, 'Student Acceptance of Using Augmented Reality Applications for Learning in Pharmacy: A Pilot Study.', Pharmacy (Basel, Switzerland), 8 1-10 (2020) [C1]
|
|
Nova |
2020 |
Graham M, Lucas CJ, Schneider J, Martin JH, Hall W, 'Translational hurdles with cannabis medicines', PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 29 1325-1330 (2020)
|
|
|
2020 |
O'Hara K, Martin JH, Schneider JJ, 'Barriers and Challenges in Performing Pharmacokinetic Studies to Inform Dosing in the Neonatal Population.', Pharmacy (Basel, Switzerland), 8 1-6 (2020) [C1]
|
|
Nova |
2020 |
Docherty T, Schneider JJ, Cooper J, 'Clinic- and Hospital-Based Home Care, Outpatient Parenteral Antimicrobial Therapy (OPAT) and the Evolving Clinical Responsibilities of the Pharmacist.', Pharmacy (Basel, Switzerland), 8 (2020) [C1]
|
|
Nova |
2020 |
Croft H, Gilligan C, Rasiah R, Levett-Jones T, Schneider J, 'Development and inclusion of an entrustable professional activity (EPA) scale in a simulation-based medicine dispensing assessment', Currents in Pharmacy Teaching and Learning, 12 203-212 (2020) [C1]
Background and purpose: Effective, safe, and patient-centred dispensing is a core task of community pharmacists. Entrustable professional activities (EPAs) offer a way of defining... [more]
Background and purpose: Effective, safe, and patient-centred dispensing is a core task of community pharmacists. Entrustable professional activities (EPAs) offer a way of defining and assessing these daily practice activities. Although EPAs have become popular within competency-based medical education programs, their use is new to pharmacy education and assessment. Educational activity and setting: A simulation-based assessment framework containing a scale of entrustment was developed to evaluate the readiness of Year 4 undergraduate pharmacy students to safely manage the supply of prescribed medicine(s) in a community pharmacy. The assessment framework was piloted in a fourth year ¿Transition to Practice¿ course with 28 simulation-based assessments conducted. Findings: An entrustment framework was developed and implemented successfully with Year 4 undergraduate pharmacy students. The EPA for medicine dispensing integrates competency domains that include information gathering, providing patient-centred care, clinical reasoning, medicine dispensing, and professional communications. On a scale ranging from level 1 to level 5, the majority (73%) of entrustment ratings were level 2 or level 3; and of the students who achieved different ratings between clinical scenarios, 75% of students improved on their second simulation attempt. There was a strong correlation between the global EPA ratings with the total score achieved across the domains. Using simulation-based assessment, entrustment decision making can be incorporated in ¿entry to profession¿ undergraduate and postgraduate pharmacy courses to assess students' readiness to transition between learning and professional practice.
|
|
Nova |
2020 |
Schneider J, Patfield M, Croft H, Salem S, Munro I, 'Introducing Augmented Reality Technology to Enhance Learning in Pharmacy Education: A Pilot Study.', Pharmacy (Basel, Switzerland), 8 (2020) [C1]
|
|
Nova |
2020 |
Croft H, Gilligan C, Rasiah R, Levett-Jones T, Schneider J, 'Developing a validity argument for a simulation-based model of entrustment in dispensing skills assessment framework.', Currents in pharmacy teaching & learning, 12 1081-1092 (2020) [C1]
|
|
Nova |
2020 |
Afrin F, Chi M, Eamens AL, Duchatel RJ, Douglas AM, Schneider J, et al., 'Can hemp help? Low-THC cannabis and non-THC cannabinoids for the treatment of cancer', Cancers, 12 (2020) [C1]
|
|
Nova |
2019 |
O Hara K, Schneider JJ, Jones AL, Wright IMR, Martin JH, Galettis P, 'Development of an UHPLC-MS/MS method for remifentanil quantification in a small plasma volume', Journal of Liquid Chromatography and Related Technologies, 42 521-527 (2019) [C1]
Remifentanil is a short acting opioid currently used in anesthesia and as an analgesic. This paper describes a simple, fast HPLC-MS/MS methodology that allows detection of remifen... [more]
Remifentanil is a short acting opioid currently used in anesthesia and as an analgesic. This paper describes a simple, fast HPLC-MS/MS methodology that allows detection of remifentanil in low volume plasma samples. Acetonitrile protein precipitation is used for sample extraction and clean up. The assay has a lower limit of detection of 0.25 ng/mL and a 3 min run time.
|
|
Nova |
2019 |
Scrimgeour S, Nunan M, Sanburg ALC, Jones A, Narkowicz C, Jacobson GA, et al., 'Pharmaceutical quality of antibiotics in Small Island Nations in the Western Pacific region: a pilot survey', Journal of Pharmacy Practice and Research, 49 426-432 (2019) [C1]
|
|
Nova |
2019 |
Hooper AD, Cooper JM, Schneider J, Kairuz T, 'Current and Potential Roles in Sports Pharmacy: A Systematic Review.', Pharmacy (Basel), 7 (2019) [C1]
|
|
Nova |
2019 |
Croft H, Gilligan C, Rasiah R, Levett-Jones T, Schneider J, 'Current Trends and Opportunities for Competency Assessment in Pharmacy Education-A Literature Review.', Pharmacy (Basel), 7 (2019) [C1]
|
|
Nova |
2018 |
Lucas CJ, Galettis P, Song S, Solowij N, Reuter SE, Schneider J, Martin JH, 'Cannabinoid Disposition After Human Intraperitoneal Use: An Insight Into Intraperitoneal Pharmacokinetic Properties in Metastatic Cancer', Clinical Therapeutics, 40 (2018)
|
|
|
2018 |
Martin JH, Schneider J, Lucas CJ, Galettis P, 'Exogenous Cannabinoid Efficacy: Merely a Pharmacokinetic Interaction?', Clinical Pharmacokinetics, 57 539-545 (2018) [C1]
Endocannabinoid pharmacology is now relatively well understood with a number of endocannabinoids and endogenous cannabinoid neurotransmitters identified and the pharmacokinetics r... [more]
Endocannabinoid pharmacology is now relatively well understood with a number of endocannabinoids and endogenous cannabinoid neurotransmitters identified and the pharmacokinetics relatively well ascertained. Further, the cannabinoid receptors are now molecularly and pharmacologically characterised and the cell processes involved in endocannabinoid transcription, synthesis, post-translational modification and protein expression are reported. Endogenous cannabinoids have been shown to have key roles in immune and pain pathways and neuro-behavioural signalling including appetite regulation. Significant recent interest has thus been shown in understanding these pathways to guide the development of agents that inhibit the natural catabolism of endogenous cannabinoids to modify pain and appetite, and to synthesise antagonists for the treatment of disease such as obesity. This research is concurrent with the renewed clinical interest in exogenous cannabinoids and their use in disease. However, the complex pharmacology and physiological effects of exogenous cannabinoids, either as individual components or in combination, as extracts or via administration of the whole plant in humans, are less well known. Yet as with all other therapeutics, including those derived from plants, knowledge of the pharmacokinetics and dynamics of the complete plant, the individual chemical molecules and their synthetic versions, including formulations and excipients is a standard part of drug development. This article covers the key pharmacological knowledge required to guide further exploration of the toxicity and efficacy of different cannabinoids and their formulations in blinded placebo-controlled studies.
|
|
Nova |
2018 |
Martin JH, Schneider J, Lucas CJ, Galettis P, 'Exogenous Cannabinoid Efficacy: Merely a Pharmacokinetic Interaction? (vol 57, pg 539, 2018)', CLINICAL PHARMACOKINETICS, 57 645-645 (2018)
|
|
|
2018 |
Croft H, Gilligan C, Rasiah R, Levett-Jones T, Schneider J, 'Thinking in Pharmacy Practice: A Study of Community Pharmacists' Clinical Reasoning in Medication Supply Using the Think-Aloud Method.', Pharmacy, 6 (2018) [C1]
|
|
Nova |
2018 |
Dryburgh LM, Bolan NS, Grof CPL, Galettis P, Schneider J, Lucas CJ, Martin JH, 'Cannabis contaminants: sources, distribution, human toxicity and pharmacologic effects.', British journal of clinical pharmacology, 84 2468-2476 (2018) [C1]
|
|
Nova |
2018 |
Lucas CJ, Galettis P, Schneider J, 'The pharmacokinetics and the pharmacodynamics of cannabinoids.', British journal of clinical pharmacology, 84 2477-2482 (2018) [C1]
|
|
Nova |
2017 |
Daneshi N, Holliday E, Hancock S, Schneider JJ, Scott RJ, Attia J, Milward EA, 'Prevalence of clinically actionable genotypes and medication exposure of older adults in the community', Pharmacogenomics and Personalized Medicine, 10 17-27 (2017) [C1]
This study analyzed clinically actionable pharmacogenotypes for clopidogrel, warfarin, statins, thiopurines, and tacrolimus using microarray data for 2121 participants (55¿85 year... [more]
This study analyzed clinically actionable pharmacogenotypes for clopidogrel, warfarin, statins, thiopurines, and tacrolimus using microarray data for 2121 participants (55¿85 years) from the Australian Hunter Community Study (HCS). At least 74% of participants (95% confidence interval [CI]: 72%¿76%) had strong level evidence for at least one medium- or high-risk actionable genotype that would trigger a change in standard therapy under current international recommendations. About 14% of these participants (95% CI: 12%¿16%) were taking medication potentially affected by the genotype in question. Furthermore, ~2.6% of all participants with medication data (95% CI: 1.4%¿3.8%) had a high-risk clinically actionable genotype for a medication to which they were exposed. This represents a considerable number of people at the population level. Although relationships between genotype and health outcomes remain contentious, pharmacogenotyping of multiple variants simultaneously may have considerable potential to improve medication safety and efficacy for older people in the community.
|
|
Nova |
2017 |
Baker J, Dickman A, Mason S, Ellershaw J, Skipper P, Schneider J, 'P-26 Challenging the pressure on nhs resources: could 48-hour continuous subcutaneous infusions (CSCIS) help? a systematically-structured review of the current evidence base', BMJ Supportive & Palliative Care, 7 A9-A10 (2017)
|
|
|
2017 |
Dickman A, Bickerstaff M, Jackson R, Schneider J, Mason S, Ellershaw J, 'Identification of drug combinations administered by continuous subcutaneous infusion that require analysis for compatibility and stability', BMC PALLIATIVE CARE, 16 (2017) [C1]
|
|
Nova |
2016 |
Galettis P, Schneider J, Martin J, 'Care with overseas purchased drugs: devil is in the detail', INTERNAL MEDICINE JOURNAL, 46 1005-1006 (2016)
|
|
|
2016 |
Schneider J, Galettis P, Williams M, Lucas C, Martin JH, 'Pill testing at music festivals: can we do more harm?', INTERNAL MEDICINE JOURNAL, 46 1249-1251 (2016)
|
|
|
2016 |
Thoopputra T, Pongmesa T, Newby DA, Schneider J, Li SC, 'Opportunistic Risk Screening for Type 2 Diabetes: Exploring of Application of Diabetes Risk Assessment Tool in Community Pharmacy in Australia and Thailand', Value in Health Regional Issues, 9 1-7 (2016) [C1]
Objective: To evaluate the feasibility of providing diabetes risk assessment at community pharmacy level in Australia and Thailand from organizational aspects. Methods: The interv... [more]
Objective: To evaluate the feasibility of providing diabetes risk assessment at community pharmacy level in Australia and Thailand from organizational aspects. Methods: The intervention study was conducted in eight community pharmacies in New South Wales, Australia, and six community pharmacies in Central Thailand. Diabetes risk assessment tools were applied to determine the risk of developing type 2 diabetes. An open-ended question was asked to solicit the willingness-to-pay value for the service. A semistructured interview was conducted with participating pharmacists to solicit the perceived facilitators and barriers in providing the service. Results: There were a total of 132 and 185 participants, with the ratio of participants in the three risk categories of low, intermediate, and high being 1:4:11 and 2:1:1.5 for Australia and Thailand, respectively. More Thai participants were willing to pay for the service (72.4% vs. 18.9%; P = 0.0001). Pharmacists from both countries agreed that providing risk assessment would increase health awareness and assist in dampening the burden of disease. A major barrier is time and staff shortage. Support from the government and collaboration among health care providers were major facilitators from Thai pharmacists' perspective, whereas remuneration was a major facilitator from Australian pharmacists' perspective. Conclusions: Pharmacists in both countries agreed that this intervention would contribute to produce positive health benefits. Differences in advantages and barriers as well as in the proportion of consumers willing to pay for the service demonstrated that it is essential for pharmacists (particularly in developing countries) to be aware of the pitfalls of copying practice initiatives in developed countries without any consideration of the local health care environment.
|
|
Nova |
2016 |
Foo LK, Duffull SB, Calver L, Schneider J, Isbister GK, 'Population pharmacokinetics of intramuscular droperidol in acutely agitated patients', British Journal of Clinical Pharmacology, 82 1550-1556 (2016) [C1]
Background: Intramuscular droperidol is used increasingly for sedation of aggressive and violent patients. This study aimed to characterise the pharmacokinetics of intramuscular d... [more]
Background: Intramuscular droperidol is used increasingly for sedation of aggressive and violent patients. This study aimed to characterise the pharmacokinetics of intramuscular droperidol in these patients to determine how rapidly it is absorbed and the expected duration of measurable drug concentrations. Methods: We undertook a population pharmacokinetic analysis of a subgroup of patients from a clinical trial comparing droperidol and midazolam: 17 receiving 5¿mg and 24 receiving 10¿mg droperidol. Droperidol was measured using high-performance liquid chromatography. Pharmacokinetic modelling was performed under a nonlinear mixed effects modelling framework (NONMEM v7.2). The model was used to simulate concentration time profiles of three typical doses, 5¿mg, 10¿mg and 10¿mg¿+¿10¿mg repeated at 15¿min. Results: A two-compartment first-order input with first-order output model fitted the data best. The absorption rate constant was poorly characterised by the data and an estimate of the first order rate constant of absorption when fixed to 10¿h¿1provided a stable model and lowest objective function. This represents extremely rapid absorption with a half-life of 5¿min. The final model had a clearance of 41.9¿l¿h¿1and volume of distribution of the central compartment of, 73.6¿l. Median and interquartile range of initial (alpha) half-life was 0.32¿h (0.26¿0.37¿h) and second (beta) half-life was 3.0¿h (2.5¿3.6¿h). Simulations indicate that 10¿mg alone provides an 80% probability of being above the lower limit of quantification (5¿µg¿l¿1) for 7¿h, 2¿h longer than for 5¿mg. Giving two 10¿mg doses increased this duration to 10¿h. Conclusions: Intramuscular droperidol is rapidly absorbed with high therapeutic concentrations after 5 and 10¿mg doses, and supports clinical data in which droperidol sedates rapidly for up to 6¿h.
|
|
Nova |
2016 |
Schneider J, O'Hara K, Munro I, 'Using Continuing Professional Development with Portfolio in a Pharmaceutics Course', PHARMACY, 4 (2016) [C1]
|
|
Nova |
2015 |
O'Hara K, Wright IMR, Schneider JJ, Jones AL, Martin JH, 'Pharmacokinetics in neonatal prescribing: Evidence base, paradigms and the future', British Journal of Clinical Pharmacology, 80 1281-1288 (2015) [C1]
Paediatric patients, particularly preterm neonates, present many pharmacological challenges. Due to the difficulty in conducting clinical trials in these populations dosing inform... [more]
Paediatric patients, particularly preterm neonates, present many pharmacological challenges. Due to the difficulty in conducting clinical trials in these populations dosing information is often extrapolated from adult populations. As the processes of absorption, distribution, metabolism and excretion of drugs change throughout growth and development extrapolation presents risk of over or underestimating the doses required. Information about the development these processes, particularly drug metabolism pathways, is still limited with weight based dose adjustment presenting the best method of estimating pharmacokinetic changes due to growth and development. New innovations in pharmacokinetic research, such as population pharmacokinetic modelling, present unique opportunities to conduct clinical trials in these populations improving the safety and effectiveness of the drugs used. More research is required into this area to ensure the best outcomes for our most vulnerable patients.
|
|
Nova |
2015 |
Hua S, Marks E, Schneider JJ, Keely S, 'Advances in oral nano-delivery systems for colon targeted drug delivery in inflammatory bowel disease: selective targeting to diseased versus healthy tissue.', Nanomedicine, 11 1117-1132 (2015) [C1]
|
|
Nova |
2015 |
Li S, Thooputra T, Schneider J, Newby D, 'A Survey of the utilization of diabetes risk assessment tool (AUSDRISK) in Disease Management: A pilot study in Australia.', Thai Bulletin of Pharmaceutical Sciences, 10 1-13 (2015)
|
|
|
2015 |
Chunyan L, Schneider J, Munro I, Li S, 'Introduction of flipped classroom model for learning in pharmacokinetics at the University of Newcastle, Australia', Chinese Journal of Medical Education, 35 312-315 (2015) [C1]
|
|
Nova |
2014 |
Schneider J, Munro I, Krishnan S, 'Using audio-visual material to enhance laboratory practicals', Journal of Teaching and Learning with Technology, 3 91-93 (2014) [C2]
|
|
|
2014 |
Schneider J, Munro I, Krishnan S, 'Flipping the Classroom for Pharmacokinetics', American Journal of Educational Research, 2 1225-1229 (2014) [C1]
|
|
Nova |
2013 |
Iwaszkiewicz KS, Schneider JJ, Hua S, 'Targeting peripheral opioid receptors to promote analgesic and anti-inflammatory actions.', Front Pharmacol, 4 132 (2013) [C1]
|
|
Nova |
2012 |
Thoopputra T, Newby DA, Schneider JJ, Li SC, 'Survey of diabetes risk assessment tools: Concepts, structure and performance', Diabetes/Metabolism Research and Reviews, 28 485-498 (2012) [C1]
|
|
Nova |
2010 |
Bobrovskaya L, Damanhuri HA, Ong LK, Schneider JJ, Dickson PW, Dunkley PR, Goodchild AK, 'Signal transduction pathways and tyrosine hydroxylase regulation in the adrenal medulla following glucoprivation: An in vivo analysis', Neurochemistry International, 57 162-167 (2010) [C1]
|
|
Nova |
2010 |
Isbister GK, O'Leary MA, Hagan J, Nichols KL, Jacoby T, Davern K, et al., 'Cross-neutralisation of Australian brown snake, taipan and death adder venoms by monovalent antibodies', Vaccine, 28 798-802 (2010) [C1]
|
|
Nova |
2010 |
Franco JL, Posser T, Gordon SL, Bobrovskaya L, Schneider JJ, Farina M, et al., 'Expression of tyrosine hydroxylase increases the resistance of human neuroblastoma cells to oxidative insults', Toxicological Sciences, 113 150-157 (2010) [C1]
|
|
Nova |
2008 |
Isbister GK, O'Leary M, Miller MK, Brown SGA, Ramasamy S, James R, Schneider JJ, 'A comparison of serum antivenom concentrations after intravenous and intramuscular administration of redback (widow) spider antivenom', British Journal of Clinical Pharmacology, 65 139-143 (2008) [C1]
|
|
Nova |
2008 |
Winter KL, Isbister GK, Schneider JJ, Konstantakopoulos N, Seymour JE, Hodgson WC, 'An examination of the cardiovascular effects of an 'Irukandji' jellyfish, Alatina nr mordens', Toxicology Letters, 179 118-123 (2008) [C1]
|
|
Nova |
2007 |
Isbister G, O'Leary M, Schneider JJ, Brown S, Currie B, 'Efficacy of antivenom against the procoagulant effect of Australian brown snake (Pseudonaja sp.) venom: In vivo and in vitro studies', Toxicon, 49 57-67 (2007) [C1]
|
|
|
2007 |
O'Leary MA, Schneider JJ, Krishnan BP, Lavis C, McKendry A, Ong LK, Isbister GK, 'Cross-neutralisation of Australian brown and tiger snake venoms with commercial antivenoms: Cross-reactivity or antivenom mixtures?', Toxicon, 50 206-213 (2007) [C1]
|
|
|
2006 |
O'Leary MA, Isbister GK, Schneider JJ, Brown SGA, Currie BJ, 'Enzyme immunoassays in brown snake (Pseudonaja spp.) envenoming: Detecting venom, antivenom and venom-antivenom complexes', Toxicon, 48 4-11 (2006) [C1]
|
|
|
2006 |
Schneider JJ, Good PD, Ravenscroft P, 'Effect of tubing on loss of clonazepam administered by continuous subcutaneous infusion', Journal of Pain and Symptom Management, 31 563-567 (2006) [C1]
|
|
|
2004 |
Good PD, Schneider JJ, Ravenscroft P, 'The Compatibility and Stability of Midazolam and Dexamethasone in Infusion Solutions', Journal of Pain and Symptom Management, 27 471-475 (2004) [C1]
|
|
|
2004 |
O'Leary MA, Schneider JJ, Isbister GK, 'Use of high performance liquid chromatography to measure tetrodotoxin in serum and urine of poisoned patients', Toxicon, 44 549-553 (2004) [C1]
|
|
|
2003 |
Rohr Y, Schneider JJ, Good P, Sattler L, 'Availability of analgesia for breakthrough pain for palliative care residents in hostels', Geriaction, 21 11-16 (2003) [C3] |
|
|
2002 |
Schneider JJ, 'Stability and compatibility of drug combinations in syringe drivers: Is it really crystal clear?', JOURNAL OF PALLIATIVE CARE, 18 227-227 (2002) |
|
|
2002 |
Schneider J, Duffy K, Page C, Atkinson P, Sketchley P, 'The sounds of music: A community collaboration project in palliative care', JOURNAL OF PALLIATIVE CARE, 18 241-241 (2002) |
|
|
2002 |
Burns J, Schneider J, O'Brien L, 'The application of handheld computers to palliative care', JOURNAL OF PALLIATIVE CARE, 18 234-234 (2002) |
|
|
2000 |
Ravenscroft PJ, Schneider JJ, 'Bedside perspectives on the use of opioids: Transferring results of clinical research into practice', Clin. Exp. Pharm. Ther, 27 529-532 (2000) [C1]
|
|
|
2000 |
Cadd AL, Keatinge DR, Henssen M, O'Brien L, Parker D, Rohr Y, et al., 'Assessment and documentation of bowel care management in palliative care: incorporating patient preferences into the care regimen', Journal of Clinical Nursing, 9, No 2 228-235 (2000) [C1]
|
|
|
1999 |
Parker D, Rohr Y, Schneider J, Thompson J, Keatinge DR, Cadd AL, et al., 'Nurses' use of patient notes to chart bowel care management for the palliative care patient', Australian Journal of Advanced Nursing, 16 36-41 (1999) [C1]
|
|
|
1998 |
Wilson KM, Schneider J, Ravenscroft PJ, 'Improved solid phase extraction technique for plasma flecainide analysis by high performance liquid chromatography', Ther. Drug Monit, 20(4) 435-438 (1998) [C1]
|
|
|
1998 |
Wilson KM, Schneider JJ, Ravenscroft PJ, 'Stability of midazolam and fentanyl in infusion solutions', J. Pain Sympt Management, 16:(1) 52-58 (1998) [C1]
|
|
|
1997 |
Schneider JJ, Wilson KM, Ravenscroft PJ, 'A study of the osmolality and pH of subcutaneous infusion solutions', Aust. J. Hosp. Pharm, 27(1) 29-31 (1997) [C1]
|
|
|
1995 |
Schneider JJ, Hart J, Newton S, Ravenscroft PJ, 'Use of morphine in palliative care patients', Australian Pharmacist, 0.589583333333333 536-538 (1995) [C1] |
|
|
1992 |
Wilkinson TJ, Robinson BA, Begg EJ, Duffull SB, Ravenscroft PJ, Schnieder JJ, 'Pharmacokinetics and efficacy of rectal versus oral sustained-release morphine in cancer patients', Cancer Chemotherapy and Pharmacology, 31 251-254 (1992)
Sustained-release morphine (MST) given by the rectal route was compared with oral MST in an open randomised cross-over trial in ten patients with cancer who received stable doses ... [more]
Sustained-release morphine (MST) given by the rectal route was compared with oral MST in an open randomised cross-over trial in ten patients with cancer who received stable doses of MST. No significant difference was found in the areas under the curve of the concentration-time profiles (AUC) following oral or rectal administration for parent morphine. The AUCs determine for morphine-6-glucuronide (M6G) and morphine-3-glucuronide (M3G) after oral administration were approximately twice those obtained following rectal administration. The maximal concentration achieved was lower and the time to maximal concentration was longer following rectal administration for morphine, M6G and M3G. The relative mean arrival times following rectal administration were significantly longer for morphine and M3G but not for M6G. These findings suggest slower absorption but less first-pass metabolism of MST after rectal administration. No significant difference was noted between the oral and the rectal route in measurements on visual-analogue scales for pain or side effects. We recommend the rectal route as being suitable for MST administration when the oral route is no longer available. In changing from oral to rectal administration, the same dose and dose interval may be used, but dose adjustment may be needed. © 1992 Springer-Verlag.
|
|
|
1992 |
Wilkinson TJ, Robinson BA, Begg EJ, Duffull SB, Ravenscroft PJ, Schneider JJ, 'Pharmacokinetics and efficacy of rectal versus oral sustained-release morphine in cancer patients', Cancer Chemother Pharmacol, 34 431-433 (1992) [C1] |
|
|
1992 |
Chen Y, Norris RL, Schneider JJ, Ravenscroft PJ, 'The influence of vancomycin concentration and pH of plasma on vancomycin protein binding', J. Pharm. Toxicol. Method, 28(1) 57-60 (1992) [C1]
|
|
|
1992 |
Schneider JJ, Ravenscroft PJ, Cavenagh JD, Brown AN, Bradley J, 'Plasma morphine-3-glucuronide, morphine-6-glucuronide and morphine concentrations in patients receiving long-term epidural morphine', BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 34 431-433 (1992) [C1]
|
|
|
1989 |
Schneider JJ, Ravenscroft PJ, 'Determination of morphine in plasma by high performance liquid chromatography with fluorescence detection', J. Chromatogr., 497 326-329 (1989) [C1]
|
|
|
1989 |
Norris RL, Taylor PJ, Schneider JJ, Ravenscroft PJ, Charles BG, 'Sensitive measurement of oxazepam in plasma by high performance liquid chromatography', J. Drug Dev., 2(2) 109-113 (1989) [C1]
|
|
|
1987 |
Charles BG, Schneider JJ, Norris RL, Ravenscroft PJ, 'Temalastine does not affect theophylline pharmacokinetics in normal subjects', 1365-2125, 24 673-675 (1987) [C1] |
|
|
1987 |
CHARLES BG, SCHNEIDER JJ, NORRIS RLG, RAVENSCROFT PJ, 'TEMELASTINE DOES NOT AFFECT THEOPHYLLINE PHARMACOKINETICS IN NORMAL SUBJECTS', BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 24 673-675 (1987)
|
|
|
1986 |
Geurrini VH, English PB, Schneider JJ, Bourne DW, 'Pharmacokinetic evaluation of a slow release cefotaxime suspension in the dog and in sheep', Am. J. Vet res, 119 81-823 (1986) [C1] |
|
|
1986 |
GUERRINI VH, ENGLISH PB, FILIPPICH LJ, SCHNEIDER J, BOURNE DWA, 'PHARMACOKINETIC EVALUATION OF A SLOW-RELEASE CEFOTAXIME SUSPENSION IN THE DOG AND IN SHEEP', AMERICAN JOURNAL OF VETERINARY RESEARCH, 47 2057-2061 (1986)
|
|
|
1986 |
GUERRINI VH, ENGLISH PB, FILIPPICH LJ, SCHNEIDER J, BOURNE DWA, 'PHARMACOKINETICS OF CEFOTAXIME IN THE DOG', VETERINARY RECORD, 119 81-83 (1986)
|
|
|
1985 |
Geurrini VH, English PB, Schneider JJ, Bourne DW, 'Pharmacokinetics of probenecid in sheep', J. Vet Pharmacol. Ther., 8(2) 128-135 (1985) [C1]
|
|
|
1984 |
SCHNEIDER JJ, TRIGGS EJ, BOURNE DWA, STEPHENS ID, HAVILAND AM, 'DETERMINATION OF OXYCODONE IN HUMAN-PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION', JOURNAL OF CHROMATOGRAPHY, 308 359-362 (1984)
|
|
|
1983 |
Tovey C, Bourne DW, Schneider JJ, Stephens ID, 'Determination of alcuronium chloride in plasma by high performance liquid chromatography', J. Chromatogr., (1983) [C1] |
|
|
1983 |
TOVEY C, BOURNE DWA, SCHNEIDER J, STEPHENS ID, TRIGGS EJ, 'DETERMINATION OF ALCURONIUM DICHLORIDE IN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITHOUT SOLVENT-EXTRACTION', JOURNAL OF CHROMATOGRAPHY, 278 216-219 (1983)
|
|
|
1982 |
SCHNEIDER JJ, 'THE DEVELOPING TECHNOLOGY AND ECONOMICS OF LARGE HELICOPTERS', VERTICA, 6 131-144 (1982)
|
|
|
1981 |
Charles BG, Schneider JJ, Ravenscroft PJ, 'Effect of metoclopramide on the bioavailability of long-acting propranolol', BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 11 517-518 (1981) [C1]
|
|
|